<DOC>
	<DOCNO>NCT02334501</DOCNO>
	<brief_summary>This open label , 2-period , fixed-sequence study 15 healthy adult subject feed condition . To evaluate effect multiple dos lansoprazole absorption pharmacokinetics ( PK ) single dose neratinib healthy subject .</brief_summary>
	<brief_title>Open-label PK Study Evaluate Lansoprazole Neratinib Healthy Subjects</brief_title>
	<detailed_description>This open label , 2-period , fixed-sequence study 15 healthy adult subject feed condition . On Day 1 Period 1 ( Treatment A ) , single oral dose neratinib administer follow PK sample 72 hour . In Period 2 ( Treatment B ) , multiple oral dos lansoprazole administer daily 7 consecutive day single oral dose neratinib administer Day 5 . PK sample neratinib take 72 hour follow neratinib dose Day 5 . The washout period least 14 day neratinib dose .</detailed_description>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Healthy , adult , men woman , 18 55 year age , inclusive , screen . Body Mass Index ≥ 18.5 ≤ 32.0 kg/m2 screening . Non moderate smoker ( 10 cigarette day least 3 month prior screen ) . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign 12lead electrocardiogram ( ECGs ) , deem principal investigator ( PI ) . Women childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose least 28 day follow last dose use one protocolspecific birth control method . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day prior first dose study drug . History presence alcoholism drug abuse within past 2 year prior screen . History presence hypersensitivity idiosyncratic reaction study drug relate compound ( eg , protonpump inhibitor [ PPIs ] ) . Women pregnant lactating . Positive result screen human immunodeficiency virus , hepatitis B surface antigen , hepatitis C virus . Unable refrain anticipates use : Any drug , include prescription nonprescription medication , herbal remedy , vitamin supplement ( include protonpump inhibitor ) begin 14 day prior first dose study drug throughout study . Acetaminophen ( 2 g per 24 hour period ) and/or loperamide ( 6 mg per 24 hour ) may permit study direction PI . Any drug know significant inducer cytochrome p450 enzyme and/or P glycoprotein , include St. John 's Wort , 28 day prior first dose study drug throughout study . Appropriate source consult PI designee confirm lack PK/pharmacodynamics interaction study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>